

# Carey K Anders

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1995578/publications.pdf>

Version: 2024-02-01

100  
papers

7,653  
citations

94433

37  
h-index

54911

84  
g-index

103  
all docs

103  
docs citations

103  
times ranked

11176  
citing authors

#	ARTICLE	IF	CITATIONS
1	<scp>HER2â€positive</scp> breast cancer brain metastasis: A new and exciting landscape. Cancer Reports, 2022, 5, e1274.	1.4	54
2	Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. , 2022, 10, e003427.		11
3	Abstract P4-10-06: Best quality care from a distance (BQual-D): Maintaining high quality care for hormone receptor positive (HR+) metastatic breast cancer (MBC) during the COVID pandemic, description of the program and provider satisfaction. Cancer Research, 2022, 82, P4-10-06-P4-10-06.	0.9	0
4	Systemic management of brain metastases in HER2+ breast cancer in 2022.. Clinical Advances in Hematology and Oncology, 2022, 20, 325-336.	0.3	0
5	Brain metastasis as first and only metastatic relapse site portends poor outcomes in patients with advanced HER2+ breast cancer.. Journal of Clinical Oncology, 2022, 40, 1045-1045.	1.6	1
6	Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase. Breast Cancer Research and Treatment, 2021, 185, 759-771.	2.5	20
7	Abstract PS13-33: Feasibility of a comprehensive monitoring protocol for the prevention and treatment of interstitial lung disease in patients undergoing treatment with fam-trastuzumab deruxtecan. Cancer Research, 2021, 81, PS13-33-PS13-33.	0.9	2
8	Inpatient palliative care utilization for patients with brain metastases. Neuro-Oncology Practice, 2021, 8, 441-450.	1.6	4
9	Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer. Current Treatment Options in Oncology, 2021, 22, 38.	3.0	24
10	Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). JNCI Cancer Spectrum, 2021, 5, pkab025.	2.9	8
11	Trial in progress: Phase 1a/b study of PF-07284890 (brain-penetrant BRAF inhibitor) with/without binimetinib in patients with BRAF V600-mutant solid tumors.. Journal of Clinical Oncology, 2021, 39, TPS3152-TPS3152.	1.6	5
12	Effect of type and timing of systemic therapy on risk of radiation necrosis in patients with HER2+ breast cancer brain metastases.. Journal of Clinical Oncology, 2021, 39, e14002-e14002.	1.6	0
13	Genomic evaluation of tumor mutational burden-high (TMB-H) versus TMB-low (TMB-L) metastatic breast cancer to reveal unique mutational features.. Journal of Clinical Oncology, 2021, 39, 1091-1091.	1.6	5
14	Impact of extracranial disease status on survival after initial central nervous system (CNS) involvement and radiation therapy in HER2+ breast cancer brain metastases (BCBM).. Journal of Clinical Oncology, 2021, 39, 1041-1041.	1.6	0
15	Identification of pathogenic CDK12 alterations in cell-free DNA (cfDNA) from patients with breast cancer.. Journal of Clinical Oncology, 2021, 39, 1028-1028.	1.6	0
16	An immunogenomic analysis of melanoma brain metastases (MBM) compared to extracranial metastases (ECM).. Journal of Clinical Oncology, 2021, 39, 9521-9521.	1.6	0
17	Development of next-generation tumor-homing induced neural stem cells to enhance treatment of metastatic cancers. Science Advances, 2021, 7, .	10.3	8
18	Cytotoxic Engineered Induced Neural Stem Cells as an Intravenous Therapy for Primary Nonâ€Small Cell Lung Cancer and Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2021, 20, 2291-2301.	4.1	1

#	ARTICLE	IF	CITATIONS
19	Outcomes in Patients With 4 to 10 Brain Metastases Treated With Dose-Adapted Single-Isocenter Multitarget Stereotactic Radiosurgery: A Prospective Study. <i>Advances in Radiation Oncology</i> , 2021, 6, 100760.	1.2	11
20	Advances in the management of breast cancer brain metastases. <i>Neuro-Oncology Advances</i> , 2021, 3, v63-v74.	0.7	10
21	A Need for More Molecular Profiling in Brain Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 785064.	2.8	1
22	Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. <i>Clinical Breast Cancer</i> , 2020, 20, 145-151.e2.	2.4	21
23	Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2~ Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 1-11.	2.4	20
24	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609.	27.0	789
25	Effects of Breast Cancer Adjuvant Chemotherapy Regimens on Expression of the Aging Biomarker, <i>p16INK4a</i> . <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa082.	2.9	15
26	Clinicopathologic features of breast cancer reclassified as HER2-amplified by fluorescence in situ hybridization with alternative chromosome 17 probes. <i>Annals of Diagnostic Pathology</i> , 2020, 48, 151576.	1.3	0
27	A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor~Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5310-5319.	7.0	102
28	What~s the Price? Toxicities of Targeted Therapies in Breast Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 55-70.	3.8	13
29	Receptor discordance in breast cancer brain metastases: when knowledge is power. <i>Neuro-Oncology</i> , 2020, 22, 1060-1061.	1.2	3
30	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2610-2619.	1.6	331
31	Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. <i>Cancer Research</i> , 2020, 80, 4314-4323.	0.9	51
32	Current multidisciplinary management of brain metastases. <i>Cancer</i> , 2020, 126, 1390-1406.	4.1	70
33	Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1005-1005.	1.6	8
34	Alliance A071701: Genomically guided treatment trial in brain metastases.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS2573-TPS2573.	1.6	4
35	Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz005.	0.7	9
36	Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors. , 2019, 7, 265.		68

#	ARTICLE	IF	CITATIONS
37	THER-06. GENOMIC AND IMMUNE CHARACTERIZATION OF TRIPLE NEGATIVE BREAST CANCER BRAIN METASTASES. <i>Neuro-Oncology Advances</i> , 2019, 1, i11-i12.	0.7	0
38	TRLS-10. MITIGATING NEUROCOGNITIVE DEFICITS FROM WHOLE-BRAIN RADIOTHERAPY IN PATIENTS WITH NUMEROUS BRAIN METASTASES VIA A NOVEL SUPEROXIDE DISMUTASE MIMETIC: RATIONALE & DESIGN OF A CLINICAL TRIAL. <i>Neuro-Oncology Advances</i> , 2019, 1, i10-i10.	0.7	0
39	BSCI-22. IDENTIFICATION OF ACTIONABLE TYROSINE KINASE-REGULATED NETWORKS REQUIRED FOR LUNG AND BREAST CANCER BRAIN METASTASIS. <i>Neuro-Oncology Advances</i> , 2019, 1, i5-i5.	0.7	0
40	The Evolving Modern Management of Brain Metastasis. <i>Clinical Cancer Research</i> , 2019, 25, 6570-6580.	7.0	83
41	ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases. <i>Future Oncology</i> , 2019, 15, 2211-2225.	2.4	16
42	Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 321-328.	2.5	17
43	Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer. <i>Oncologist</i> , 2019, 24, 762-771.	3.7	56
44	TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2019, 37, 1081-1089.	1.6	251
45	The Promise of Immunotherapy for Breast Cancer Brain Metastases. <i>Current Breast Cancer Reports</i> , 2019, 11, 241-247.	1.0	7
46	Brain metastases. <i>Nature Reviews Disease Primers</i> , 2019, 5, 5.	30.5	579
47	Live birth outcomes after adolescent and young adult breast cancer. <i>International Journal of Cancer</i> , 2018, 142, 1994-2002.	5.1	16
48	TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5â€“Fluorouracil-Based Chemotherapy. <i>Clinical Breast Cancer</i> , 2018, 18, e301-e304.	2.4	5
49	Changing Natural History of HER2â€“Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies. <i>Clinical Breast Cancer</i> , 2018, 18, 29-37.	2.4	35
50	LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 637-648.	2.5	40
51	Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. <i>Annals of Translational Medicine</i> , 2018, 6, 163-163.	1.7	86
52	Multidisciplinary Management of Breast Cancer During Pregnancy. <i>Oncologist</i> , 2017, 22, 324-334.	3.7	54
53	Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. <i>Neuro-Oncology</i> , 2017, 19, 1481-1493.	1.2	32
54	The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	89

#	ARTICLE	IF	CITATIONS
55	Birth Outcomes Among Adolescent and Young Adult Cancer Survivors. <i>JAMA Oncology</i> , 2017, 3, 1078.	7.1	68
56	Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, 1469-1480.	1.2	42
57	Discerning Clinical Responses in Breast Cancer Based On Molecular Signatures. <i>American Journal of Pathology</i> , 2017, 187, 2199-2207.	3.8	18
58	Systemic Therapy in the Setting of Central Nervous System (CNS) Metastases in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2017, 9, 217-226.	1.0	0
59	Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5687-5695.	7.0	170
60	Coordination of Care for Breast Reconstruction Patients: A Provider Survey. <i>Clinical Breast Cancer</i> , 2017, 17, e59-e64.	2.4	3
61	Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. <i>Journal of Clinical Investigation</i> , 2017, 127, 3472-3483.	8.2	130
62	LCCC 1025: Phase II study of everolimus, trastuzumab, and vinorelbine for HER2+ breast cancer brain metastases (BCBM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1011-1011.	1.6	3
63	Number of tumor-infiltrating lymphocytes in breast cancer brain metastases compared to matched breast primaries.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2049-2049.	1.6	4
64	The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 34-42.	3.8	85
65	Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma. <i>Cancer</i> , 2016, 122, 1017-1028.	4.1	106
66	Activity of trastuzumab-emtansine (TDM1) in HER2-positive breast cancer brain metastases: A case series. <i>Cancer Treatment Communications</i> , 2016, 7, 43-46.	0.4	36
67	Endocrine therapy and urogenital outcomes among women with a breast cancer diagnosis. <i>Cancer Causes and Control</i> , 2016, 27, 1325-1332.	1.8	8
68	Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT <sup>®</sup> nanoparticle formulation against non-small-cell lung cancer brain metastases. <i>Nanomedicine</i> , 2016, 11, 1947-1955.	3.3	23
69	Whole Brain Radiotherapy for Brain Metastases. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 393.	7.4	5
70	A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience. <i>Oncologist</i> , 2016, 21, 16-20.	3.7	33
71	Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations. <i>Journal of Clinical Oncology</i> , 2016, 34, 2303-2311.	1.6	80
72	ANG1005, a novel brain-penetrant taxane derivative, for the treatment of recurrent brain metastases and leptomeningeal carcinomatosis from breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2004-2004.	1.6	16

#	ARTICLE	IF	CITATIONS
73	Management of brain metastases in breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 686-8.	0.3	1
74	Multidisciplinary Management of Breast Cancer Brain Metastases. <i>Oncology</i> , 2016, 30, 923-33.	0.5	8
75	Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of <i>BRCA</i> -Mutated and <i>BRCA</i> Wild-Type Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 920-930.	4.1	62
76	Local iontophoretic administration of cytotoxic therapies to solid tumors. <i>Science Translational Medicine</i> , 2015, 7, 273ra14.	12.4	56
77	Recurrence-free Survival Among Patients With ER+/PR+/HER2 Breast Cancers is Predicted by Expression of the Estrogen Response Signature. <i>FASEB Journal</i> , 2015, 29, 926.2.	0.5	1
78	Molecular Classification Predicts Outcome Among Patients With ER+/PR+/HER2 Breast Cancers. <i>FASEB Journal</i> , 2015, 29, 284.10.	0.5	0
79	$\beta$ -Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain. <i>Clinical Cancer Research</i> , 2014, 20, 56-67.	7.0	87
80	TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 557-566.	2.5	59
81	Approaches for optimal drug development and clinical trial design for breast cancer brain metastasis. <i>Oncology</i> , 2014, 28, 579, 584-5.	0.5	1
82	The Management of Early-Stage and Metastatic Triple-Negative Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 737-749.	2.2	80
83	Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer. <i>Oncologist</i> , 2013, 18, 123-133.	3.7	454
84	Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e61359.	2.5	77
85	New targets for triple-negative breast cancer. <i>Oncology</i> , 2013, 27, 846-54.	0.5	24
86	Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 523-535.	2.5	189
87	Treatment of Breast Cancer Brain Metastases. <i>Current Breast Cancer Reports</i> , 2012, 4, 1-9.	1.0	10
88	Stratifying triple-negative breast cancer: which definition(s) to use?. <i>Breast Cancer Research</i> , 2011, 13, 105.	5.0	28
89	Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. <i>Breast Cancer Research</i> , 2011, 13, R125.	5.0	87
90	The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. <i>Cancer</i> , 2011, 117, 1602-1611.	4.1	125

#	ARTICLE	IF	CITATIONS
91	Breast Carcinomas Arising at a Young Age: Unique Biology or a Surrogate for Aggressive Intrinsic Subtypes?. <i>Journal of Clinical Oncology</i> , 2011, 29, e18-e20.	1.6	200
92	Poly(ADP-Ribose) Polymerase Inhibition: Targeted Therapy for Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 4702-4710.	7.0	149
93	Breast Cancer Before Age 40 Years. <i>Seminars in Oncology</i> , 2009, 36, 237-249.	2.2	574
94	Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2009, 9, S73-S81.	2.4	546
95	Treating in the Dark: Unanswered Questions on Costs and Benefits of Late Line Therapy for Metastatic Breast Cancer. <i>Cancer Investigation</i> , 2009, 27, 13-16.	1.3	6
96	GnRH: Authors' Response. <i>Journal of Women's Health</i> , 2009, 18, 1473-1473.	3.3	0
97	Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression. <i>Journal of Clinical Oncology</i> , 2008, 26, 3324-3330.	1.6	695
98	Age-Specific Differences in Oncogenic Pathway Deregulation Seen in Human Breast Tumors. <i>PLoS ONE</i> , 2008, 3, e1373.	2.5	81
99	Understanding and treating triple-negative breast cancer. <i>Oncology</i> , 2008, 22, 1233-9; discussion 1239-40, 1243.	0.5	179
100	Systemic Therapy Type and Timing Effects on Radiation Necrosis Risk in HER2+ Breast Cancer Brain Metastases Patients Treated With Stereotactic Radiosurgery. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4